Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 18Other solid neoplasm 18Gastrointestinal 3Head & Neck 2Gynecologic 2Genitourinary 2Dermatologic 2Breast 2

Conditions

Triple Negative Breast Neoplasms 163Breast Neoplasms 162Carcinoma, Non-Small-Cell Lung 60Melanoma 44Ovarian Neoplasms 42Colorectal Neoplasms 37Carcinoma, Renal Cell 36Squamous Cell Carcinoma of Head and Neck 33Pancreatic Neoplasms 29Stomach Neoplasms 28Neoplasm Metastasis 27Uterine Cervical Neoplasms 24Neoplasms 24Endometrial Neoplasms 24Lung Neoplasms 19Head and Neck Neoplasms 19Esophageal Neoplasms 18Carcinoma, Transitional Cell 18Carcinoma, Hepatocellular 16Urinary Bladder Neoplasms 14Small Cell Lung Carcinoma 14Prostatic Neoplasms 14Parkinson Disease 4, Autosomal Dominant Lewy Body 13Sarcoma 10Mesothelioma 9Kidney Neoplasms 9Cholangiocarcinoma 9Carcinoma, Ovarian Epithelial 9Carcinoma, Merkel Cell 9Fallopian Tube Neoplasms 8

Interventions

pembrolizumab 2Cyclophosphamide 2Cisplatin 2sargramostim 1regorafenib 1fludarabine 1entinostat 1durvalumab 1cemiplimab 1avelumab 1atezolizumab 1abemaciclib 1Surgical Procedures, Operative 1Psychiatric Rehabilitation 1Polymerase Chain Reaction 1Platinum 1Pemetrexed 1Paclitaxel 1Nivolumab 1Midazolam 1Microarray Analysis 1Megestrol Acetate 1Levoleucovorin 1Leucovorin 1Letrozole 1LY3023414 1Interleukin-2 1Interferon-gamma 1Interferon-alpha 1Immunoenzyme Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × pembrolizumab × Breast × Clear all
NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

NuCana plc

Phase 1/2 Terminated
19 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05086692 2025-07-09

ABILITY-1

Medicenna Therapeutics, Inc.

Phase 1/2 Recruiting
115 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡